Neovii is an independent, global biopharmaceutical company with a patient-focused mission to develop and bring to market novel life-transforming therapies to improve the outcomes in transplantation medicine, hemato-oncological and immune disorders. Neovii was founded in 2013 by the acquisition of Fresenius Biotech inheriting more than three decades of experience in speciality pharmaceuticals. Neovii’s global headquarters are located in Rapperswil, Switzerland, its U.S headquarters are in Waltham, MA, and its biologics manufacturing site and German operations are located in Gräfelfing, Germany. Neovii employs approx. 150 employees and has presence in nearly 60 countries worldwide.